



US00RE39150E

(19) **United States**
 (12) **Reissued Patent**
Krall et al.

(10) **Patent Number:** **US RE39,150 E**
 (45) **Date of Reissued Patent:** **Jun. 27, 2006**

(54) **COMPOSITION FOR CREATING VASCULAR OCCLUSIONS**

(75) Inventors: **Robert E. Krall**, Alpine, CA (US);
Charles W. Kerber, La Mesa, CA (US); **Kimberly Knox**, La Mesa, CA (US)

(73) Assignee: **Prohold Technologies, Inc.**, El Cajon, CA (US)

(21) Appl. No.: **09/823,775**

(22) Filed: **Mar. 30, 2001**

Related U.S. Patent Documents

Reissue of:

(64) Patent No.: **6,037,366**
 Issued: **Mar. 14, 2000**
 Appl. No.: **09/151,621**
 Filed: **Sep. 11, 1998**

U.S. Applications:

(60) Provisional application No. 60/058,510, filed on Sep. 11, 1997.

(51) **Int. Cl.**
A61K 31/275 (2006.01)
A61K 31/12 (2006.01)
A61K 31/05 (2006.01)
A61K 33/24 (2006.01)
A61K 33/42 (2006.01)

(52) **U.S. Cl.** **514/527**; 514/526; 514/690;
 514/730; 514/558; 514/560; 514/824; 514/834;
 514/930; 514/944; 514/970; 424/601; 424/605;
 424/617; 424/649; 424/78.08; 424/78.31;
 424/78.35; 424/78.37; 424/422; 604/49;
 604/53

(58) **Field of Classification Search** 514/527,
 514/526, 690, 730, 558, 560, 824, 834, 930,
 514/944, 970; 424/601, 605, 617, 649, 78.08,
 424/78.31, 78.37, 78.35, 422; 604/49, 53

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,740,534 A * 4/1988 Matsuda et al. 523/111
 5,525,334 A * 6/1996 Ito et al. 424/78.35
 5,624,685 A * 4/1997 Takahashi et al. 424/488
 5,695,480 A * 12/1997 Evans et al. 604/264
 5,702,361 A * 12/1997 Evans et al. 604/53
 5,759,194 A * 6/1998 Hammerslag 606/214
 5,795,331 A * 8/1998 Cragg et al. 604/96
 6,143,352 A * 11/2000 Clark et al. 427/2.1
 6,174,919 B1 * 1/2001 Hickey 514/519
 6,476,069 B1 * 11/2002 Krall et al. 514/527
 2002/0018752 A1 * 2/2002 Krall et al. 424/9.4
 2003/0194389 A1 * 10/2003 Porter 424/78.35

FOREIGN PATENT DOCUMENTS

WO 99/42535 * 8/1999

OTHER PUBLICATIONS

Barr, John D., "Temporary and Permanent Occlusion of Cerebral Arteries," *Neuroendovascular Surgery*, vol. 11, No. 1, Jan. 2000, pp. 27-38.

Berthelsen, B. et al., "Embolization of Cerebral Arteriovenous Malformations with Bucrylate," *Acta Radiologica*, vol. 31, 1990, pp. 13-21.

Freeny, Patrick C. et al., "Transcatheter Therapy of Genitourinary Abnormalities Using Isobutyl 2-Cyanoacrylate (Bucrylate)," *AJR*, vol. 133, Oct. 1979 pp. 647-656.

Gobin, Dr. Y. Pierre et al., "Treatment of Brain Arteriovenous Malformations by Embolization and Radiosurgery," *J Neurosurg*, vol. 85, 1996, pp. 19-28.

Halbach, Dr. Van V. et al., "Preoperative Balloon Occlusion of Arteriovenous Malformations," *Neurosurgery*, vol. 22, No. 2, 1988, pp. 301-308.

Kerber, Dr. Charles W. and Wong, Wade, "Liquid Acrylic Adhesive Agents in Interventional Neuroradiology," *Neuroendovascular Surgery*, vol. 11, No. 1, Jan. 2000, pp. 85-99.

Lefkowitz, Dr. Michael A. et al., "Balloon-assisted Guglielmi Detachable Coiling of Wide-necked Aneurysms: Part II—Clinical Results," *Neurosurgery*, vol. 45, No. 3, Sep. 1999, pp. 531-538.

Levy, Dr. David I., "Embolization of Wide-necked Anterior Communication Artery Aneurysm: Technical Note," *Neurosurgery*, vol. 41, No. 4, Oct. 1997, pp. 979-982.

Malek, Dr. Adel M. et al., "Balloon-assist Technique for Endovascular Coil Embolization of Geometrically Difficult Intracranial Aneurysms," *Neurosurgery*, vol. 46, No. 6, Jun. 2000, pp. 1397-1407.

Mericle, Robert A., M.D., "Temporary Balloon Protection as an Adjunct to Endosaccular Coiling of Wide-necked Cerebral Aneurysms," *Neurosurgery*, vol. 41, No. 4, Oct. 1997, pp. 1992-1998.

Moret, J et al., "The "Remodeling Technique" in the Treatment of Wide Neck Intracranial Aneurysms," *Interventional Neuroradiology*, vol. 3, 1997, pp. 21-35.

Pelz, David M. et al., "Preoperative Embolization of Brain AVMs with Isobutyl-2 Cyanoacrylate," *AJNR*, vol. 9, Aug. 1988, pp. 757-764.

Rao, V.R.K. et al., "Dissolution of Isobutyl 2-Cyanoacrylate on Long-Term Follow-Up," *AJNR*, vol. 10, Jan./Feb. 1989, pp. 135-141.

Spiegel, S. M. et al., "Adjusting the Polymerization Time of Isobutyl-2 Cyanoacrylate," *American Journal of Neuroradiology*, vol. 7, Jan./Feb. 1986, pp. 109-112.

Vinuela, F.V. et al., "Dominant-Hemisphere Arteriovenous Malformations: Therapeutic Embolization with Isobutyl-2-Cyanoacrylate," *AJNR*, vol. 4, Jul./Aug. 1983, pp. 959-966.

(Continued)

Primary Examiner—John Pak

(74) Attorney, Agent, or Firm—Gray Cary Ware & Freidenrich, LLP

(57) **ABSTRACT**

A composition including 2-hexyl cyanoacrylate and goal is useful in treating arteriovenous malformations (AVMs) and other body lumens to be blocked.

5 Claims, No Drawings

OTHER PUBLICATIONS

Vinuela, Fernando et al., "Progressive Thrombosis of Brain Arteriovenous Malformations After Embolization with Isobutyl 2-Cyanoacrylate," *AJNR*, vol. 4, Nov./Dec. 1983, pp. 1233-1238.

Vinuela, Fernando et al., "Angiographic Follow-Up of Large Cerebral AVMs Incompletely Embolized with Isobutyl-2-Cyanoacrylate," *AJNR*, vol. 7, Sep./Oct. 1986, pp. 919-925.

* cited by examiner

COMPOSITION FOR CREATING VASCULAR OCCLUSIONS

Matter enclosed in heavy brackets [] appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue.

This [application] is a reissue of Ser. No. 09/159,621, filed Sep. 11, 1998, now U.S. Pat. No. 6,032,366, which claims the benefit of U.S. Provisional Application No. 60/058,510, filed on Sep. 11, 1997.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to a composition used to treat arteriovenous malformations ("AVMs") and other vascular abnormalities. The composition includes a cyanoacrylate liquid monomer and gold in a prepolymerized polymer of cyanoacrylate. The composition is placed into the body lumen via standard catheter procedures or directly percutaneously.

2. Description of the Related Art

AVMs and vascular tumors, especially those of the brain, are exceedingly difficult to treat. These growths may occur all over the body, but are especially difficult to treat when in the brain or brain stem. The composition of the invention is especially useful in treating neurological AVMs, but may also be used to treat tumors anywhere in the body.

Cyanoacrylate adhesives have been used surgically but are limited in their usefulness by cytotoxicity and heat generation. The brain is unusually sensitive to cytotoxicity and heat.

The art described in this section is not intended to constitute an admission that any patent, publication or other information referred to herein is "prior art" with respect to this invention, unless specifically designated as such. In addition, this section should not be construed to mean that a search has been made or that no other pertinent information as defined in 37 C.F.R. § 1.56(a) exists.

SUMMARY OF THE INVENTION

The invention provides a composition that may be placed in a body lumen including veins and arteries by super selective catheterization or direct puncture using standard tools of the interventional angiographer. The composition of the invention has been successfully tested in simulated models of the AVMs and tumors under fluoroscopy and in systems that closely resembles the neurological condition of the human body. Further studies have been done in the pig rete. The rete is a body of fine arteries that allows the blood to flow into the pig brain which closely resembles normal human AVMs.

The composition is a cyanoacrylate which involves mixing two separate containers of the material immediately prior to administration of the material into the AVM by catheter. The composition may contain seven ingredients which are divided into two parts prior to mixture and use. It furnishes properties that are useful for closing neurological AVMs. The product can also be used to close any growth resembling an AVM in any part of the body. Because of the sensitive nature of the tissues in the brain, the general sensitivity of the product must be controlled. In less sensitive areas, the product will work equally as well.

Part I consists of a cyanoacrylate liquid monomer containing pure phosphoric acid (250 ppm) hydroquinone (100

ppm) and P-methoxyphenol (1200 ppm). This composition is stable and unchanging we believe for over two years. The container in which Part I is stored requires cleaning and preparation before such stability can be achieved. The liquid monomer of choice for this usage is 2-hexyl cyanoacrylate.

Part II consists of pure powdered gold (5×3 microns), a small amount of prepolymerized polymer of the same cyanoacrylate and ethyl myristate. Any of the large chain fatty acid esters will work to replace ethyl myristate so long as they are liquids.

The pre-polymerized polymers of cyanoacrylate are unstable and change their structures and properties even in the solid state. The change is exponential and therefore the polymer must be used within a limited amount of time before deterioration occurs.

The polymer is prepared by addition of part 1 to a rapidly stirring weak bicarbonate-water solution. The addition must be added drop-wise to avoid unpolymerized masses from forming. The solid polymer is washed thoroughly with pure water to remove any traces of bicarbonate, then washed thoroughly with pure methanol to remove the water. Methanol dries rapidly and when the polymer is further dried at a high reduced pressure for 16–18 hours, it is considered dry. The polymer must be used in the next step within 24 hours to obtain consistent results in the final product. This mixture must be sterilized within 72 hours from the time of preparation.

Part II is sterilized with ethylene oxide gas with the stopper held in an open position. Ethylene oxide is an alkylating agent and after sterilization the prepolymerized polymer is stable. Hence, the stability and sterilization of part 2 are carried out simultaneously. The sterilized samples of Part II are capped in a clean room under sterile handling conditions.

The pre-polymerized polymer can be stabled by treatment with any of the strong alkylating agents, like ethylene oxide, ketone, etc.

This composition of matter has good cohesion as well as adequate adhesion to function well for AVMs and other similar uses within the vascular tree. The cohesion keeps the material together during the time required for it to polymerize. The adhesion makes it stick to the artery walls.

The polymerized device will cause a modest but desirable inflammatory response in the treated tissues.

A Formulation for Arteriovenous Malformations and Tumors

It is desirable to prepare a formulation for the intravascular occlusion of AVMs and Tumors that will have the following properties:

The product has a very slow rate of biodegradation.

Both liquid and solid forms should have excellent cohesion.

The delivered product should have medium adhesion

The delivered product must be radiopaque.

The solid polymer should be soft and pliable.

The delivered product must have a very low or negligible histotoxicity.

The deposited product must have no long term negative properties such as carcinogenicity, teratogenicity, systemic toxicity or other unpredictable biological and medical effects.

The products must be sterile.

The delivered product must have good few characteristics for selective catheterization.

3

The product must be stable on storage for an extended period of time.

The formulation should be made from pure products and be reproducible for simple manufacturing procedures. The product formulation is:

Part I (M1)	
2-Hexyl Cyanoacrylate	999,550 ppm
Hydroquinone	100 ppm
p-Methoxyphenol	100 ppm
Pure Phosphoric Acid	250 ppm
Part II (M2)	
Pure Gold	1.0000 g
Pure Ethyl Myristate	0.5000 g
FMS*	0.0200 g

*FMS is a specially prepared polymer of 2-hexyl cyanoacrylate and must be used within 24 hours of preparation or will change and be unusable. Further, it must be sterilized within 72 hours.

Each item of this formulation is critical to the proper performance of the product.

2-Hexyl Cyanoacrylate

This cyanoacrylate homolog was chosen because it biodegrades very slowly in blood or any living tissue. The secondary alcohol will biodegrade several thousand times slower than its primary derivative. This very slow degradation rate also lowers greatly the histotoxicity.

Hydroquinone

When the amount of hydroquinone is reduced by half (50 ppm) the product shows low shelf life stability. Large amounts over 100 ppm do not seem to effect the product stability. This inhibitor lowers the effect of the high energy free radicals that may appear in the cyanoacrylate.

p-Methoxyphenol

The slow polymerization of cyanoacrylates even under refrigeration is caused by low energy free radicals. When 100 ppm of p-methoxyphenol is present this slow polymerization is prevented and long term stability is achieved. Less p-methoxyphenol (50 ppm) will not protect the product.

Sulfur Dioxide

The faintest trace of sulfur dioxide is present in the product. One part per million can be seen and less is present. However, this very faint trace adds to the stability of Neuracryl* ml in the ampule.

Gold

Tantalum, platinum and gold are all radiopaque. Gold was best for us because it could be suspended colloiddally in the mixture. One gram of gold is used per device.

Ethyl Myristate

Subbicates, fatty acid esters and other plasticizers, are useful for fastening the polymers of the cyanoacrylates. they also will stabilize the pre-formed polymers of the cyanoacrylates so that they may be used as thickeners. We have chosen ethyl myristate, an esterified, biocompatible

4

fatty acid because of the convenience of purification and analysis and because it works well to give the formulation the desirable properties.

FMS

5 FMS is the polymer of 2-hexyl cyanoacrylate formed in a weak, aqueous sodium bicarbonate solutions. The polymer diners in structure and size depending on how it is formed. This polymer will remain stable until M2 can be formulated. The polymer must be formed and dried completely before use. The final formulation of M2 must occur within 24 hours because the ethyl myristate stabilized FMS until sterilization can be performed. After sterilization the product is stable for several years.

Neuracryl M

15 M1 and M2 are mixed immediately before use. The mixture should be used within 4 hours after mixing. If there is a delay, the syringe should be turned over several times a minute to resuspend the gold which will be settled.

What is claimed is:

20 1. A composition for creating therapeutic vascular occlusions in an animal comprising a mixture of:

(a) Part 1 comprised of 2-hexyl cyanoacrylate, hydroquinone, p-methoxyphenol and phosphoric acid; and

25 (b) Part 2 comprising gold metal powder, [ethyl myristate and a sterilized] *a large chain fatty acid ester in liquid form and a stabilized polymer of 2-hexylcyanoacrylate [in weak aqueous bicarbonate solution]*.

30 2. The composition of claim 1 wherein Part 1 comprises about 100 PPM hydroquinone, 100 PPM p-methoxyphenol, 250 PPM phosphoric acid and the remainder 2-hexyl cyanoacrylate.

35 3. The composition of claim 2 wherein Part 2 comprises about 65 percent by weight gold, about 30 percent by weight ethyl myristate and the remainder said [sterilized] *stabilized polymer of 2-hexylcyanoacrylate [in weak aqueous bicarbonate solution]*.

40 4. The composition of claim 1 wherein Part 2 includes sulfur dioxide as a stabilizer.

5. A method for creating therapeutic vascular occlusions in an animal needing therapeutic vascular occlusion comprising the steps of:

45 (a) Mixing together Part 1 comprised of 2-hexyl cyanoacrylate, hydroquinone, p-methoxyphenol and phosphoric acid with Part 2 comprising gold metal powder, [ethyl myristate and a sterilized] *a large chain fatty acid ester in liquid form, and a stabilized polymer of 2-hexylcyanoacrylate [in weak aqueous bicarbonate solution]*; and

50 (b) [injecting] *administering* the mixture into a vascular site needing occlusion [with the gold metal powder suspended in the mixture].

* * * * *